A feature in The New Yorker explores how Daniela Schiller, PhD, from the Mount Sinai School of Medicine’s Brain Imaging Core in New York City, has approached a kind of memory erasure for people who have suffered greatly from post-traumatic stress disorder (PTSD) with the aid of cutting-edge neuroimaging.

The Christie NHS Foundation Trust in Manchester, U.K., is the newest institution to join an assembly of organizations with the objective of researching an integrated and real-time MR-guided radiotherapy system for more accurate treatment delivery, according to today’s announcement from Elekta and Philips Healthcare.

A preliminary imaging study with Zn-63 zinc citrate confirmed a protocol for preparation and showed encouraging preclinical biodistribution. This technique holds promise for a wide variety of diseases involving zinc disorder, including a range of cancers and metabolic disorders, according to a study published July 21 in the Journal of Nuclear Medicine.

The FDA announced July 14 that a shortage of Technetium Tc99m Exametazime Injection, also known as the Ceretec Kit (GE Healthcare, Medi-Physics), is in effect and expected to continue until the first week of August.

Alzheimer's disease is characterized by the hallmark pathology of beta-amyloid plaque and tau protein tangles, but there appears to be a new protein on the block in the development of the neurodegenerative disease. It is called TAR DNA binding protein of 43kDa (TDP-43), according to research presented during the 2014 international conference of the Alzheimer's Association (AAIC).

Finding tau deposition in the brain could be a way to verify Alzheimer's prior to the arrival of all the characteristic symptoms, according to a study presented during this week's Alzheimer's Association International Conference (AAIC) 2014.

The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET. In another study, patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer's disease.

IBA announced this week that the FDA has provided marketing authorization for the gantry beam line designed for the company’s compact proton therapy system, which will be used much like its larger cousins for the treatment of a variety of cancers.